Description of risk factors at the index ACS in the 3122 fully eligible referents population according to APA use immediately postindex ACS
| Referents | Clopidogrel | Ticagrelor | Prasugrel | No-P2Y12 |
| n=839 | n=1148 | n=549 | Antagonist n=586 | |
| Age, in years (mean, SD) at index | 70.7 (12.5) | 61.5 (12.3) | 57.8 (10.4) | 65.5 (14.0) |
| Median age, in years (range) | 71.8 (31.2; 97.6) | 60.3 (25.8; 94.2) | 58.0 (30.8; 88.0) | 65.6 (27.7; 98.2) |
| Male (N, %) | 560 (66.7%) | 885 (77.1%) | 467 (85.1%) | 440 (75.1%) |
| iACS=1st UA (N, %) | 116 (13.8%) | 58 (5.1%) | 24 (4.4%) | 89 (15.2%) |
| iACS=1st MI (N, %) | 541 (64.5%) | 974 (84.8%) | 472 (86.0%) | 392 (66.9%) |
| iACS=Rec ACS (N, %) | 182 (21.7%) | 116 (10.1%) | 53 (9.7%) | 105 (17.9%) |
| If iACS=1st MI | STEMI | 234 (27.9%) | 552 (48.1%) | 372 (67.8%) | 168 (28.7%) |
| BMI, in kg/m2 (median) | 26.2 (16.4; 46.6) | 26.7 (16.5; 49.9) | 26.6 (17.5; 49.2) | 26.3 (14.7; 46.3) |
| Diabetes (N, %) | 217 (25.9%) | 217 (18.9%) | 94 (17.1%) | 166 (28.3%) |
| Hypertension (N, %) | 816 (97.3%) | 1128 (98.3%) | 537 (97.8%) | 565 (96.4%) |
| Hyperlipidaemia (N, %) | 808 (96.3%) | 1139 (99.2%) | 539 (98.2%) | 541 (92.3%) |
| CV comorbidity (N, %) | 240 (28.7%) | 113 (9.9%) | 37 (6.8%) | 129 (22.1%) |
| Severe comorbidity | 234 (28.1%) | 285 (24.9%) | 94 (17.2%) | 141 (24.2%) |
| Aspirin (N, %) | 600 (71.5%) | 1140 (99.3%) | 544 (99.1%) | 327 (55.8%) |
| Anticoagulant (N, %) | 153 (18.2%) | 17 (1.5%) | 11 (2.0%) | 74 (12.6%) |
| Coronary bypass (N, %) | 27 (3.3%) | 12 (1.0%) | 1 (0.2%) | 90 (15.4%) |
| Angioplasty (N, %) | 636 (75.8%) | 1050 (91.5%) | 530 (96.5%) | 275 (47.1%) |
ACS, acute coronary syndrome; APA, antiplatelet agent (other than aspirin); BMI, body mass index; CV comorbidities, cardiovascular comorbidities (ie, history of stroke, cardiac failure, peripheral artery disease, atrial fibrillation); iACS, index ACS; MI, myocardial infarction; STEMI, ST-elevated myocardial infarction; UA, unstable angina.